cofepris glp-1 news Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the FDA Adverse Event Reporting System Risks of Ozempic, other GLP-1

Chronological Vs Biological Age: What Is The Difference

Niacinamide , ,

The guidelines state, GLP-1 RAs may be considered for weight-loss in patients who have completed cancer therapy and may be considered with caution for patients on stable endocrine-based cancer therapies based on limited observational safety data. They also say, GLP-1 RAs cannot be recommended currently for patients receiving or initiating chemotherapies and/or immunotherapies due to lack of safety and outcomes data. Iyengar is director of Survivorship Services at Winship Cancer Institute of Emory University, a clinical member of Winships Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor-in-chief of the journal ONCOLOGY

This report also consists of IRIS analysis using numerous other datasets such as social media conversations, paid media spend, earned media coverage, clinical trials, and peer-reviewed publication monitoring

Puca, L